BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $13 from $11 and keeps a Buy rating on the shares. ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive, Flatiron Health integrates clonoSEQ MRD testing into OncoEMR
- Craig-Hallum bullish on Adaptive Biotechnologies, initiates with a Buy
- Adaptive Biotechnologies initiated with a Buy at Craig-Hallum
- Adaptive Biotechnologies Holds Annual Shareholders Meeting
- Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress